BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16930497)

  • 1. Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.
    Thomas CA; Chuang YC; Giannantoni A; Chancellor MB
    Curr Urol Rep; 2006 Jul; 7(4):266-71. PubMed ID: 16930497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum-A toxin: an exciting new treatment option for prostatic disease.
    Thomas CA; Guercini F; Chuang YC; Chancellor MB
    Int J Clin Pract Suppl; 2006 Dec; (151):33-7. PubMed ID: 17169009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential and promise of using botulinum toxin in the prostate gland.
    Chuang YC; Giannantoni A; Chancellor MB
    BJU Int; 2006 Jul; 98(1):28-32. PubMed ID: 16831138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
    Hsu YC; Wang HJ; Chuang YC
    Toxins (Basel); 2016 Apr; 8(5):. PubMed ID: 27128942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of botulinum toxin in the prostate.
    Chuang YC; Chancellor MB
    J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature.
    Moore DC; Cohn JA; Dmochowski RR
    Toxins (Basel); 2016 Mar; 8(4):88. PubMed ID: 27023601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
    Chiang BJ; Kuo HC; Liao CH
    Toxins (Basel); 2019 Sep; 11(9):. PubMed ID: 31546892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial.
    Robert G; Descazeaud A; Karsenty G; Saussine C; Azzouzi AR; de la Taille A; Desgrandchamps F; Faix A; Fourmarier M; Georget A; Benard A; Barry Delongchamps N
    World J Urol; 2018 Jun; 36(6):921-929. PubMed ID: 29383480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin A for male lower urinary tract symptoms.
    Chartier-Kastler E; Mehnert U; Denys P; Giuliano F
    Curr Opin Urol; 2011 Jan; 21(1):13-21. PubMed ID: 21099691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin A in prostate disease: a venom from bench to bed-side.
    Mearini L; Giannantoni A
    Curr Drug Deliv; 2012 Jan; 9(1):85-94. PubMed ID: 22409179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.
    Chung E
    Expert Opin Biol Ther; 2015 Jan; 15(1):95-102. PubMed ID: 25347039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
    de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
    Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction.
    Jhang JF; Kuo HC
    Toxins (Basel); 2018 Jun; 10(7):. PubMed ID: 29949878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin injection for lower urinary tract dysfunction.
    Kuo YC; Kuo HC
    Int J Urol; 2013 Jan; 20(1):40-55. PubMed ID: 22571329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
    Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
    BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
    Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.
    Silva J; Pinto R; Carvalho T; Botelho F; Silva P; Silva C; Cruz F; Dinis P
    BJU Int; 2011 Jun; 107(12):1950-4. PubMed ID: 21105985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of botulinum toxin in benign prostatic hyperplasia.
    Marchal C; Perez JE; Herrera B; Machuca FJ; Redondo M
    Neurourol Urodyn; 2012 Jan; 31(1):86-92. PubMed ID: 21905088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case for bladder botulinum toxin application.
    Kim DK; Thomas CA; Smith C; Chancellor MB
    Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses.
    Arnouk R; Suzuki Bellucci CH; Benatuil Stull R; de Bessa J; Malave CA; Mendes Gomes C
    ScientificWorldJournal; 2012; 2012():463574. PubMed ID: 22997495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.